Teleflex Incorporated

NYSE:TFX

Medical - Instruments & Supplies

Healthcare
$165.85 +0.83%

+$1.04 today

Market cap
$6.58B
Beta
0.82
P/E (TTM)
-5.5
EPS (TTM)
-$22.79
Dividend yield
1.08%
52W Low $100.18High $139.67

Volume 1.16M

Average 0.80M

TFX Interest Income

Income earned on cash, deposits, and investments held by the company.

Teleflex IncorporatedNYSE: TFX

Interest Income · Q2 FY2026 · quarter ended Jun 2026

Interest income declines year over year

Q2 FY2026 interest income of $1.42M fell 13.8% year over year, behind the -12.0% change in trailing-twelve-month interest income. Sequentially, it fell 17.1% from the prior quarter. Over 3 fiscal years it compounded at +91.5% a year.

Context

  • Interest income amounted to 0.3% of revenue in FY2025, unchanged from a year earlier.
  • Interest income increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -13.8% toward the trailing-twelve-month pace of -12.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.42M-17.1% QoQ
Last fiscal yearDec 2025
$6.4M-20.1% YoY
LTMJun 2026
$7.14M-12.0% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-13.8%——
1 year-20.1%——
3-year CAGR+91.5%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
6.4M USD
Year-over-year change
-20.1%
4-year CAGR
+48.2%

Interest Income vs competitors

How TFX compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -12.0% is the 5th highest of 8, against a peer median of -6.7%.
  • Interest income amounts to 0.3% of revenue for TFX, versus a peer median of 0.3%.
TFX Competitors
Interest Income for TFX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PCVXVaxcyte, Inc.LTM Jun 2026$108.08M USD-15.9%+142.9%—
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$57.86M USD+55.2%+55.8%12.8%
ALKSAlkermes plcLTM Sep 2026$32.5M USD-27.1%+81.1%1.9%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$15.68M USD-1.4%+225.0%1.0%
BLCOBausch + Lomb CorporationLTM Jun 2026$14M USD-6.7%+26.0%0.3%
KRYSKrystal Biotech, Inc.LTM Jun 2026$7.95M USD-73.0%+75.4%1.8%
TFXTeleflex IncorporatedLTM Jun 2026$7.14M USD-12.0%+91.5%0.3%
STVNStevanato Group S.p.A.LTM Jun 2026€2.07M EUR+104.4%+168.1%0.2%
TGTXTG Therapeutics, Inc.LTM Sep 2026$0 USD——0.0%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$0 USD——0.0%
CRSPCRISPR Therapeutics AGLTM Sep 2026$0 USD——0.0%
Peer median (excluding TFX) —-6.7%+81.1%0.3%

Competitors are the stored peer set for TFX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.81B2.79B2.97B3.05B1.99B
Cost of Revenue1.26B1.26B1.33B1.34B871.96M
Gross Profit1.55B1.53B1.65B1.7B1.12B
Gross Margin55.2%54.9%55.4%55.9%56.2%
Research & Development130.84M153.82M154.35M161.67M144.78M
Selling, General & Admin860.09M863.75M929.87M995.27M720.17M
Operating Expenses921.51M1.03B1.14B1.55B864.95M
Depreciation & Amortization237.36M230.59M242.12M274.6M177.74M
EBITDA853.8M730.77M761.21M433.62M302.51M
EBITDA Margin30.4%26.2%25.6%14.2%15.2%
Operating Income628.1M499.73M506.31M151.01M255.8M
Operating Margin22.4%17.9%17.0%5.0%12.8%
Interest Income1.33M912K12.78M8.01M6.4M
Interest Expense56.97M54.26M85.08M83.54M100.22M
Other Income / Expenses(68.63M)(53.81M)(72.3M)(75.54M)(231.25M)
Income Before Tax559.47M445.92M434.01M75.48M24.55M
Pre-Tax Margin19.9%16.0%14.6%2.5%1.2%
Income Tax Expense74.35M83M76.44M5.32M(33.98M)
Net Income485.37M363.14M356.33M69.68M(905.64M)
Net Margin17.3%13.0%12.0%2.3%-45.4%
EPS (Basic)10.387.747.581.49(20.30)
EPS (Diluted)10.237.687.531.48(20.25)
Weighted Avg Shares46.77M46.9M46.98M46.84M44.62M
Weighted Avg Shares (Diluted)47.43M47.31M47.3M47.09M44.72M

Teleflex Incorporated

NYSE:TFX

Intrinsic Alpha fair value

Locked

Current Price

$165.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.